EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intravenous zoledronate for pediatric langerhans cell histiocytosis with bone involvement

Jann Adriel Sy, Thuan Chong Quah, Pian Pian Tee, Cindy Wei Li Ho

Frontiers in Pediatrics · 29.04.2026 · 14

DOI: 10.3389/fped.2026.1825076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 29.04.2026. Verfasst von Jann Adriel Sy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bone involvement in pediatric Langerhans cell histiocytosis (LCH) causes pain, functional impairment, and frequent relapse, creating a need for adjunctive therapies with rapid skeletal benefit. At National University Hospital, Singapore, a tertiary pediatric hematology-oncology referral centre, we retrospectively evaluated eight children with osseous LCH treated with intravenous zoledronate between January 2020 and December 2025. Three had multisystem disease (two risk-organ–positive), four had multifocal bone LCH, and one had unifocal bone LCH. Pain response (clinical improvement) and radiologic outcome (lesion stability or sclerosis) and adverse effects, and concurrent therapies were recorded. Prior treatment exposure was heterogeneous, ranging from no prior systemic therapy to multi-agent chemotherapy, oral maintenance therapy, targeted therapy, radiotherapy, pamidronate, and indomethacin. Zoledronate was given for painful active bone lesions, particularly in weight-bearing sites, and in selected patients for progressive relapsed osseous disease, poor tolerance of oral chemotherapy, or as a chemotherapy-sparing bone-directed approach. Zoledronate was started at a median age of 60 months. All 4 symptomatic patients experienced pain improvement (100%), with a median time to improvement of 18 days post-infusion. Among 8 patients with imaging follow-up, 2 exhibited complete radiographic resolution and 6 showed improvement. The treatment was well tolerated; transient fever occurred in 4 patients. Three patients received concomitant oral chemotherapy for active systemic disease, either in other systems or in new bone lesions. No cases of clinically significant hypocalcemia or osteonecrosis of the jaw were observed.

Schlagwörter

Stichwörter der Autor:innen

Langerhans cell histiocytosisbisphosphonate therapypediatric bone lesionsskeletal relapsezoledronate

Autor:innen und Institutionen

  • Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Khoo Teck Puat - National University Children's Medical Institute, National University Health System, Singapore, Singapore.
  • Department of Paediatrics, Sabah Women and Children Hospital, Sabah, Malaysia.

Zitieren

APA

Sy, J. A., Quah, T. C., Tee, P. P., & Ho, C. W. L. (2026). Intravenous zoledronate for pediatric langerhans cell histiocytosis with bone involvement. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1825076

Vancouver

Sy JA, Quah TC, Tee PP, Ho CWL. Intravenous zoledronate for pediatric langerhans cell histiocytosis with bone involvement. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1825076

BibTeX
@article{Sy2026,
  author = {Sy, Jann Adriel and Quah, Thuan Chong and Tee, Pian Pian and Ho, Cindy Wei Li},
  title = {Intravenous zoledronate for pediatric langerhans cell histiocytosis with bone involvement},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1825076}
}
Kostenlos starten →